Tributary Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Tributary Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-9,100	Closed	-$1.55M	–	223
2020 Q4	$1.55M	Sell	9,100 -1,800	-17%	-$267K	0.11%	118
2020 Q3	$1.53M	Sell	10,900 -800	-7%	-$122K	0.13%	123
2020 Q2	$1.88M	Sell	11,700 -3,000	-20%	-$408K	0.16%	98
2020 Q1	$1.44M	Buy	14,700 +2,900	+25%	+$331K	0.15%	104
2019 Q4	$1.52M	Buy	+11,800	New	+$1.19M	0.11%	120
2019 Q3	–	Sell	-13,300	Closed	-$2.02M	–	218
2019 Q2	$2.02M	Hold	13,300	–	–	0.14%	88
2019 Q1	$1.58M	Hold	13,300	–	–	0.12%	112
2018 Q4	$1.45M	Buy	13,300 +2,700	+25%	+$338K	0.13%	107
2018 Q3	$1.71M	Buy	+10,600	New	+$1.45M	0.13%	111

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Tributary Capital Management's SRPT Position: Q1 2021 in Review

Tributary Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 9,100 shares — an estimated $1.55M sold.

Tributary Capital Management first reported a position in SRPT in Q3 2018 and held it in 9 quarters. The position peaked at $2.02M in Q2 2019. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Tributary Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
Tributary Capital Management sold 9,100 Sarepta Therapeutics shares in Q1 2021, an estimated $1.55M.
Tributary Capital Management first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 9 quarters.
Tributary Capital Management's Sarepta Therapeutics position peaked at $2.02M in Q2 2019.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Tributary Capital Management's 13F filing for Q1 2021, filed 20 Apr 2021.